Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs KeyCorp — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.44 (market cap $5.85B), while KeyCorp trades at $20.1 (market cap $21.16B). The key difference: KeyCorp is far larger — about 3.6× Iovance Biotherapeutics Inc. Common Stock's market cap, and KeyCorp pays a 4.14% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and KeyCorp for 66 Days on average.
| IOVA | KEY | |
|---|---|---|
Market Cap | $5.85B | $21.16B |
Volume | 14,517,176 | 16,207,672 |
Sector | Health | Financials |
52-Week High | $14.82 | $23.99 |
52-Week Low | $1.81 | $16.78 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $5.78B | $34.34B |
Dividend Yield | — | 4.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KeyCorp (KEY) trades at $20.1, down 0.2% on the day, with a bearish technical signal from moving averages despite recent earnings beats. The stock shows attractive valuation with a P/E of 11.6 and a P/B of 1.22, supported by a strong net income margin of 26.72%. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments aimed at strengthening operations.
The outlook is positive with a consensus price target of $25.00, implying significant upside, driven by loan growth and net interest margin expansion. Risks include competitive pressure from peers raising dividends and macroeconomic sensitivity to interest rate changes. Earnings momentum and institutional buying provide a solid foundation for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
